Spectrum reports record EPS after boosting Fusilev sales
This article was originally published in Scrip
Executive Summary
Spectrum Pharmaceuticals had $46.5 million in first quarter 2012 net income and record-breaking earnings per share of $0.71 – both three times the $12.8 million in net income and $0.23 in earnings per share reported for first quarter 2011 – based on $51 million in sales of its metastatic colorectal cancer drug Fusilev (levolecovorin) and operational efficiency.